TPG (NASDAQ: TPG), a leading global alternative asset management firm, announced a significant strategic growth investment in K2 Medical Research (K2), an integrated clinical trial site platform specializing in central nervous system trials for leading pharma and biotech sponsors. TPG is partnering with K2’s management team to continue building a world-class research platform. Terms were not disclosed. Latham & Watkins LLP represented TPG in the investment with a corporate team led by Boston partner John Miller and New York partners Justin Hamill and Michael Benjamin, with associates Jennifer Boyd, Matthew Sieben, and Olivia Pettingill. Advice was also provided on tax matters by Bay Area partner Katharine Moir, with associate Andrea Herman; on healthcare matters by Washington, D.C. counsel Nicole Liffrig Molife, with associate Margaret Rote; on FDA matters by Washington, D.C. counsel Monica Groat, with associate Evan Miller; on data privacy/HIPAA matters by Bay Area partner Heather Deixler, with associate Mitch Bennett; on intellectual property matters by Bay Area partner Michelle Gross, with associate Ryan Sanders; on employee benefits and compensation matters by New York partner Erin Murphy; on labor and employment matters by New York counsel Sandra Benjamin, with associate Sahar Merchant; on anti-bribery and anti-corruption matters by Bay Area partner Scott Joiner, with associates Chris D'Agostino and Heather Artinian; on real estate matters by Chicago partner Robert Buday and New York counsel Karen Ritter; on environmental matters by Washington, D.C. partner James Barrett, with associate Brittany Curcuru; on ESG matters by New York partner Betty Huber, with associate Preeti Grewal; and on antitrust matters by Bay Area partner Kelly Fayne and Washington, D.C. partner Patrick English, with associate Sydney Kirlan-Stout.~~